With identification of the isocitrate–dehydrogenase (IDH) mutation in codon 132 of IDH1 (or infrequently in codon 172 of IDH2) as being the most common molecular genetic alteration in grade II and grade III gliomas, immunohistochemical data using antibodies specific to IDH1 R132H mutant protein have revealed a more widespread tumor cell distribution than expected. This evidence concerns the gene IDH1 and neoplasm.